| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $37.2M | — | -57.1% |
| R&D Expense | $15.2M | — | +42.5% |
| SG&A Expense | $65.2M | — | -10.1% |
| Operating Income | -$68.9M | — | -157.6% |
| Pre-tax Income | -$68.5M | — | -165.6% |
| Income Tax | -$15.3M | — | -120.7% |
| Net Income | -$53.2M | — | -182.1% |
| EPS (Basic) | -$0.44 | — | -158.8% |
| EPS (Diluted) | -$0.44 | — | -158.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $91.4M | -2.5% | -16.9% |
| Accounts Receivable | $116.9M | -46.2% | +13.2% |
| Inventory | $28.4M | -4.1% | -3.1% |
| Current Assets | $268.5M | -25.9% | +0.1% |
| Total Assets | $520.0M | -13.2% | +11.3% |
| Current Liabilities | $76.0M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $21.1M | — | +206.0% |
| Capital Expenditures | $3.1M | — | -13.2% |
| Investing Cash Flow | -$3.1M | — | +13.2% |
| Financing Cash Flow | -$20.2M | — | -883.1% |
| Free Cash Flow | $18.0M | — | +176.3% |
| +16.9% |
| Total Liabilities | $138.6M | -15.9% | +39.6% |
| Stockholders' Equity | $244.6M | -18.5% | +0.7% |